HGBL With MYC and BCL2 and/or BCL6 Rearrangements
specificHigh-grade B-cell lymphoma characterized by the abnormal rearrangement of MYC gene, BCL2 gene, and/or BCL6 gene. Patients with this type of lymphoma usually respond poorly to standard treatments and have a poor prognosis.
5
Centers
5
Active Trials
—
Cancer Funding
Top Centers for HGBL With MYC and BCL2 and/or BCL6 Rearrangements(5)
Ranked by research excellence score (trials · grants · publications). Methodology →
| # | Center | Score |
|---|---|---|
| 1 | Abramson Cancer Center of the University of PennsylvaniaPhiladelphia, PA NCI Comprehensive Active Research Program | 60.0 |
| 2 | Winship Cancer InstituteAtlanta, GA NCI Comprehensive Active Research Program | 60.0 |
| 3 | University of Colorado Cancer CenterAurora, CO NCI Comprehensive Active Research Program | 60.0 |
| 4 | The University of Kansas Cancer CenterKansas City, KS NCI Comprehensive Active Research Program | 60.0 |
| 5 | Rutgers Cancer InstituteNew Brunswick, NJ NCI Comprehensive Active Research Program | 60.0 |
Research tier badges reflect trial volume, NIH grant funding, and publication impact — not clinical outcomes or patient satisfaction. Learn about our methodology →